<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="1-part\PMC6631137\results\search\disease\results.xml">
  <result pre="traditional design of effective vaccines for rapidly-evolving pathogens, such as" exact="influenza" post="A virus, has failed to provide broad spectrum and"/>
  <result pre="demonstrated the potential to facilitate the design of a universal" exact="influenza" post="vaccine. However, few studies have integrated computational optimization in"/>
  <result pre="T-cell epitopes. Interactions between virus-host-environment determine the evolvability of the" exact="influenza" post="population. We propose that with the development of novel"/>
  <result pre="will be crucial for the development of a long-lasting universal" exact="influenza" post="vaccine. Taken together, computational approaches are powerful and promising"/>
  <result pre="powerful and promising tools for the development of a universal" exact="influenza" post="vaccine with durable and broad protection. Universal influenza vaccine"/>
  <result pre="a universal influenza vaccine with durable and broad protection. Universal" exact="influenza" post="vaccine computational design interactions of virus-host-environment 1. Introduction In"/>
  <result pre="lasting protection for human populations. This is particularly true for" exact="influenza" post="viruses, a single-stranded, negative sense RNA virus. One of"/>
  <result pre="One of the important weapons being developed to effectively prevent" exact="influenza" post="virus infection is a vaccine that can provide durable"/>
  <result pre="those that may cause potential pandemics, that is, a universal" exact="influenza" post="vaccine [1]. The National Institute of Allergy and Infectious"/>
  <result pre="and Infectious Diseases (NIAID) has defined the criteria for universal" exact="influenza" post="vaccine, which includes (1) being at least 75% effective"/>
  <result pre="which includes (1) being at least 75% effective against symptomatic" exact="influenza" post="infection; (2) protecting against group I and group II"/>
  <result pre="influenza infection; (2) protecting against group I and group II" exact="influenza" post="A viruses (influenza B would be a secondary target);"/>
  <result pre="design novel broadly-reactive vaccine candidates, which have been used for" exact="influenza" post="and other pathogens [2]. These new approaches have revealed"/>
  <result pre="the genomic era can aid in achieving goals of universal" exact="influenza" post="vaccine design. However, it has found limited applications in"/>
  <result pre="briefly summarize the currently applied approaches of seasonal and universal" exact="influenza" post="vaccine design and their disadvantages (part 2), gather information"/>
  <result pre="necessary resources and efforts needed for computational approaches of universal" exact="influenza" post="vaccine candidates (part 4). We will explore the important"/>
  <result pre="computational advances that could help in restructuring the existing seasonal" exact="influenza" post="vaccine design and contribute to the development of universal"/>
  <result pre="influenza vaccine design and contribute to the development of universal" exact="influenza" post="vaccine. 2. Current Approach for Influenza Vaccine Design 2.1."/>
  <result pre="for Seasonal Vaccine Design To prevent infections from circulating seasonal" exact="influenza" post="viruses, the annually administered influenza virus vaccines contain H1N1"/>
  <result pre="prevent infections from circulating seasonal influenza viruses, the annually administered" exact="influenza" post="virus vaccines contain H1N1 (phylogenetic group 1 hemagglutinin), H3N2"/>
  <result pre="group 1 hemagglutinin), H3N2 (phylogenetic group 2 hemagglutinin) and two" exact="influenza" post="B virus components (Victoria-like and Yamagata-like) [7]. The vaccine"/>
  <result pre="components (Victoria-like and Yamagata-like) [7]. The vaccine candidates from natural" exact="influenza" post="virus strains are recommended by the World Health Organization"/>
  <result pre="of vaccine strains to make recommendation on the components of" exact="influenza" post="vaccine [8]. The evaluations are mainly based on viral"/>
  <result pre="at least 6-8 months to produce sufficient global supplies of" exact="influenza" post="vaccine via current vaccine production technologies with egg-based, cell-based"/>
  <result pre="vaccine [9,10]. For a comprehensive review of traditional approaches for" exact="influenza" post="vaccine selection, design, development and challenges refer to this"/>
  <result pre="by Wong and Webby [11]. Influenza vaccines selected from natural" exact="influenza" post="virus strains predominantly elicit specific antibodies against the globular"/>
  <result pre="annual vaccines, demonstrating severely low and unstable immune protection from" exact="influenza" post="infection [18]. Predictive models of viral evolution to forecast"/>
  <result pre="[18]. Predictive models of viral evolution to forecast dominant circulating" exact="influenza" post="viral strains in the upcoming influenza seasons through the"/>
  <result pre="to forecast dominant circulating influenza viral strains in the upcoming" exact="influenza" post="seasons through the analysis of genetic and epidemiological data"/>
  <result pre="seasons through the analysis of genetic and epidemiological data from" exact="influenza" post="surveillance system have been developed to make quantitative predictions"/>
  <result pre="viral evolution and aim to improve the selection of seasonal" exact="influenza" post="vaccine candidates [10,19]. This framework has demonstrated potential to"/>
  <result pre="has demonstrated potential to integrate multiple data sources to improve" exact="influenza" post="vaccine design. 2.2. Universal Influenza Vaccine Design Seasonal vaccines"/>
  <result pre="vaccines offer a little or no protection to emerging zoonotic" exact="influenza" post="viruses with pandemic potential, as many species, especially wild"/>
  <result pre="are recognized as the natural reservoir of all subtypes of" exact="influenza" post="A viruses and have the potential to occur spillover"/>
  <result pre="have the potential to elicit broadly protective antibodies against seasonal" exact="influenza" post="strain. M2-based universal vaccine design focuses on the conserved"/>
  <result pre="domain [25]. While the stalk domain is conserved across multiple" exact="influenza" post="subtypes, it is shielded by the immune-dominant head domain."/>
  <result pre="and protective vaccines for hypervariable and rapidly-evolving viral pathogens, including" exact="influenza" post="viruses [30,31]. The reasons for this failure include inherent"/>
  <result pre="vaccine design often ignores the underlying processes of the global" exact="influenza" post="meta-population which generates diversity that allows the viral populations"/>
  <result pre="fit the needs of universal vaccine design for highly diverse" exact="influenza" post="virus in several promising aspects [38,39]: (1) being able"/>
  <result pre="assessment and prediction. Computational approaches to identify candidates for universal" exact="influenza" post="vaccine design have been used with a variety of"/>
  <result pre="both, to tackle with the high degree of variability in" exact="influenza" post="viruses by boosting the immunity from the conserved or"/>
  <result pre="severity. Particularly, memory CD4+ T-cells can provide substantial protection against" exact="influenza" post="infection through direct effector mechanisms as well as indirect"/>
  <result pre="[72,73,74,75,76,77,78]. Taken together, these studies suggest that an epitope-based universal" exact="influenza" post="vaccine can be developed by selecting the well-conserved and"/>
  <result pre="be developed by selecting the well-conserved and immunodominant epitopes across" exact="influenza" post="subtypes using the immunomics approach. A major challenge in"/>
  <result pre="in Clinical Development There are currently three promising epitope-based universal" exact="influenza" post="vaccines, FP-01.1, Flu-v and Multimeric-001 (M-001) are at different"/>
  <result pre="(PB1 and PB2) and have high level conservancy across H1-H9" exact="influenza" post="A subtypes with wider population coverage. The phase I"/>
  <result pre="epitopes derived from NP, matrix proteins (M1 and M2) from" exact="influenza" post="A and NP from influenza B viruses and are"/>
  <result pre="proteins (M1 and M2) from influenza A and NP from" exact="influenza" post="B viruses and are conserved across most influenza viruses"/>
  <result pre="NP from influenza B viruses and are conserved across most" exact="influenza" post="viruses with high population coverage [81,82]. The phase II"/>
  <result pre="and also induced antibody response [83]. Multimeric-001 (M-001), a universal" exact="influenza" post="epitope-based vaccine, is currently at the pivotal phase III"/>
  <result pre="conserved and common epitopes from NP, M1, and HA of" exact="influenza" post="A and B viruses to activate both humoral and"/>
  <result pre="system to provide multi-strain protection from the seasonal and pandemic" exact="influenza" post="viruses [85]. The predicted population coverage of these selected"/>
  <result pre="approaches to prevent infections from remerging or emerging highly evolving" exact="influenza" post="viruses. 3.2.3. Computational Approaches that Incorporate Host Immunological Factors"/>
  <result pre="[89,94]. These technologies and bioinformatics tools can be applied to" exact="influenza" post="virus vaccine design with creating library of antibody repertoire"/>
  <result pre="generated consensus sequences for NA protein of H1N1 and several" exact="influenza" post="proteins of H5N1, including HA, NA and matrix protein"/>
  <result pre="rounds of consensus generation. Within each phylogenetic subclade of the" exact="influenza" post="virus subtype, the primary consensus with the most common"/>
  <result pre="immune targets. Phylogenetic evolutionary models have been used to infer" exact="influenza" post="viral evolutionary history for decades with molecular data, including"/>
  <result pre="[44] developed an ancestral sequence reconstruction method for highly pathogenic" exact="avian influenza" post="(HPAI) H5N1 surface proteins HA and NA. Based on"/>
  <result pre="developed an ancestral sequence reconstruction method for highly pathogenic avian" exact="influenza" post="(HPAI) H5N1 surface proteins HA and NA. Based on"/>
  <result pre="of these viruses. These ancestral sequences were synthesized into attenuated" exact="influenza" post="viruses that could replicate. Their cross-reactive protection against H5N1"/>
  <result pre="vaccine design, the computational approach is promising. Precise estimation of" exact="influenza" post="virus evolution including protein structural and its functional information"/>
  <result pre="heritable phenotype [123]. The zoonotic nature and complicated ecology of" exact="influenza" post="viruses make evolvability more difficult to quantify and predict."/>
  <result pre="and potentially interact to shape viral phylogenies�? [124,125]. Dynamics of" exact="influenza" post="virus infections and transmissions at individual-level (such as viral"/>
  <result pre="experimental testing can be integrated together to improve prediction on" exact="influenza" post="virus evolvability. For example, experimental studies designed to assess"/>
  <result pre="which can improve the prediction of viral evolvability for natural" exact="influenza" post="virus strains [127]. The potential predictors and consequent mutations"/>
  <result pre="enhance our understanding on viral characteristics, potential immune escape, or" exact="influenza" post="antiviral drug resistance [128]. Challenges for this area are"/>
  <result pre="ameliorate the output from computational modeling [19,129,130]. Compared to other" exact="infectious disease" post="sampling, influenza viruses have already established an excellent global"/>
  <result pre="from computational modeling [19,129,130]. Compared to other infectious disease sampling," exact="influenza" post="viruses have already established an excellent global network of"/>
  <result pre="a large amount of genetic data has been available for" exact="influenza" post="research. However, three main limitations exist in current surveillance:"/>
  <result pre="the unequal sampling in zoonotic hosts is more severe. Human" exact="influenza" post="outbreaks have been well monitored and sampled [129]. However,"/>
  <result pre="can provide an initial rationalization and optimal sample size for" exact="avian influenza" post="virus surveillance [129,133,134]. The affiliated sequence meta-data records have"/>
  <result pre="provide an initial rationalization and optimal sample size for avian" exact="influenza" post="virus surveillance [129,133,134]. The affiliated sequence meta-data records have"/>
  <result pre="access database platforms have facilitated the accessibility and sharing of" exact="influenza" post="sequence data to the science community. Despite the availability"/>
  <result pre="have been using the traditional approaches to design and develop" exact="influenza" post="vaccines. The rapid genetic changes and antigenic drift of"/>
  <result pre="influenza vaccines. The rapid genetic changes and antigenic drift of" exact="influenza" post="virus populations result in short-term protection necessitating continual vaccine"/>
  <result pre="the interactions of host- pathogen-environment that produced important insights into" exact="influenza" post="disease dynamics across biological scales. Integrating these computational and"/>
  <result pre="can facilitate the development of a broadly cross-reactive, evolutionarily-resistant universal" exact="influenza" post="vaccine. Acknowledgments We thank Lambodhar Damodaran and Jiani Chen"/>
  <result pre="DiseasesJ. Infect. Dis.201821834735410.1093/infdis/jiy10329506129 2.RappuoliR.AderemA.A 2020 vision for vaccines against HIV," exact="tuberculosis" post="and malariaNature201147346346910.1038/nature1012421614073 3.MedinaR.A.StertzS.ManicassamyB.ZimmermannP.SunX.AlbrechtR.A.Uusi-KerttulaH.ZagordiO.BelsheR.B.FreyS.E.et al.Glycosylations in the Globular Head of"/>
  <result pre="the Promise of Applied Evolutionary BiologyTrends Microbiol.20182610211810.1016/j.tim.2017.09.00429097090 11.WongS.-S.WebbyR.J.Traditional and new" exact="influenza" post="vaccinesClin. Microbiol. Rev.20132647649210.1128/CMR.00097-1223824369 12.AndersonC.S.OrtegaS.ChavesF.A.ClarkA.M.YangH.TophamD.J.DeDiegoM.L.Natural and directed antigenic drift of"/>
  <result pre="Microbiol. Rev.20132647649210.1128/CMR.00097-1223824369 12.AndersonC.S.OrtegaS.ChavesF.A.ClarkA.M.YangH.TophamD.J.DeDiegoM.L.Natural and directed antigenic drift of the H1" exact="influenza" post="virus hemagglutinin stalk domainSci. Rep.201771461410.1038/s41598-017-14931-729097696 13.Berlanda ScorzaF.TsvetnitskyV.DonnellyJ.J.Universal influenza vaccines:"/>
  <result pre="the H1 influenza virus hemagglutinin stalk domainSci. Rep.201771461410.1038/s41598-017-14931-729097696 13.Berlanda ScorzaF.TsvetnitskyV.DonnellyJ.J.Universal" exact="influenza" post="vaccines: Shifting to better vaccinesVaccine2016342926293310.1016/j.vaccine.2016.03.08527038130 14.SkowronskiD.M.JanjuaN.Z.De SerresG.SabaiducS.EshaghiA.DickinsonJ.A.FonsecaK.WinterA.L.GubbayJ.B.KrajdenM.et al.Low 2012–13"/>
  <result pre="Not Antigenic Drift in Circulating VirusesPLoS ONE20149e9215310.1371/journal.pone.009215324667168 15.ZostS.J.ParkhouseK.GuminaM.E.KimK.Diaz PerezS.WilsonP.C.TreanorJ.J.SantA.J.CobeyS.HensleyS.E.Contemporary H3N2" exact="influenza" post="viruses have a glycosylation site that alters binding of"/>
  <result pre="16.WuN.C.ZostS.J.ThompsonA.J.OyenD.NycholatC.M.McBrideR.PaulsonJ.C.HensleyS.E.WilsonI.A.A structural explanation for the low effectiveness of the seasonal" exact="influenza" post="H3N2 vaccinePLoS Pathog.201713e100668210.1371/journal.ppat.100668229059230 17.PaulesC.I.SullivanS.G.SubbaraoK.FauciA.S.Chasing Seasonal Influenza—The Need for a"/>
  <result pre="Prediction for Human Influenza VirusesTrends Microbiol.20182611913110.1016/j.tim.2017.09.00129032900 20.WebsterR.G.BeanW.J.GormanO.T.ChambersT.M.KawaokaY.Evolution and ecology of" exact="influenza" post="A virusesMicrobiol. Rev.1992561521791579108 21.GuanY.VijaykrishnaD.BahlJ.ZhuH.WangJ.SmithG.J.D.The emergence of pandemic influenza virusesProtein"/>
  <result pre="ecology of influenza A virusesMicrobiol. Rev.1992561521791579108 21.GuanY.VijaykrishnaD.BahlJ.ZhuH.WangJ.SmithG.J.D.The emergence of pandemic" exact="influenza" post="virusesProtein Cell2010191310.1007/s13238-010-0008-z21203993 22.SmithG.J.D.BahlJ.VijaykrishnaD.ZhangJ.PoonL.L.ChenH.WebsterR.G.PeirisJ.S.GuanY.Dating the emergence of pandemic influenza virusesProc."/>
  <result pre="of pandemic influenza virusesProtein Cell2010191310.1007/s13238-010-0008-z21203993 22.SmithG.J.D.BahlJ.VijaykrishnaD.ZhangJ.PoonL.L.ChenH.WebsterR.G.PeirisJ.S.GuanY.Dating the emergence of pandemic" exact="influenza" post="virusesProc. Natl. Acad. Sci. USA2009106117091171210.1073/pnas.090499110619597152 23.NeumannG.NodaT.KawaokaY.Emergence and pandemic potential"/>
  <result pre="Acad. Sci. USA2009106117091171210.1073/pnas.090499110619597152 23.NeumannG.NodaT.KawaokaY.Emergence and pandemic potential of swine-origin H1N1" exact="influenza" post="virusNature200945993193910.1038/nature0815719525932 24.ZhangH.WangL.CompansR.W.WangB.-Z.Universal Influenza Vaccines, a Dream to Be Realized"/>
  <result pre="Be Realized SoonViruses20146197410.3390/v605197424784572 25.JangY.H.SeongB.L.Options and obstacles for designing a universal" exact="influenza" post="vaccineViruses201463159318010.3390/v608315925196381 26.KirchenbaumG.A.RossT.M.Eliciting broadly protective antibody responses against influenzaCurr. Opin."/>
  <result pre="protective antibody responses against influenzaCurr. Opin. Immunol.201428717610.1016/j.coi.2014.02.00524632083 27.SauttoG.A.KirchenbaumG.A.RossT.M.Towards a universal" exact="influenza" post="vaccine: Different approaches for one goalVirol. J.2018151710.1186/s12985-017-0918-y29370862 28.CarterD.M.DarbyC.A.LefoleyB.C.CrevarC.J.AlefantisT.OomenR.AndersonS.F.StrugnellT.Cortés-GarciaG.VogelT.U.Design and"/>
  <result pre="Hemagglutinin Vaccine for H1N1 Influenza VirusesJ. Virol.2016904720473410.1128/JVI.03152-1526912624 29.JobE.R.YsenbaertT.SmetA.ChristopoulouI.StrugnellT.OlooE.O.OomenR.P.KleanthousH.VogelT.U.SaelensX.Broadened immunity against" exact="influenza" post="by vaccination with computationally designed influenza virus N1 neuraminidase"/>
  <result pre="Virol.2016904720473410.1128/JVI.03152-1526912624 29.JobE.R.YsenbaertT.SmetA.ChristopoulouI.StrugnellT.OlooE.O.OomenR.P.KleanthousH.VogelT.U.SaelensX.Broadened immunity against influenza by vaccination with computationally designed" exact="influenza" post="virus N1 neuraminidase constructsNPJ Vaccines201835510.1038/s41541-018-0093-130510776 30.HeL.ZhuJ.Computational tools for epitope"/>
  <result pre="particle vaccinesClin. Vaccine Immunol.20121912813910.1128/CVI.05533-1122190399 35.ShuY.McCauleyJ.GISAID: Global initiative on sharing all" exact="influenza" post="data––From vision to realityEurosurveillance2017223049410.2807/1560-7917.ES.2017.22.13.3049428382917 36.NCBI Influenza virus databaseAvailable online:"/>
  <result pre="databaseAvailable online: https://www.ncbi.nlm.nih.gov/genomes/FLU/Database/nph-select.cgi?go=database(accessed on 28 April 2019) 37.collab: WHOFluID—A global" exact="influenza" post="epidemiological data sharing platformWHO2017Available online: https://www.who.int/influenza/surveillance_monitoring/fluid/en/(accessed on 5 March"/>
  <result pre="40.NabelG.J.FauciA.S.Induction of unnatural immunity: Prospects for a broadly protective universal" exact="influenza" post="vaccineNat. Med.2010161389139110.1038/nm1210-138921135852 41.GilesB.M.RossT.M.A computationally optimized broadly reactive antigen (COBRA)"/>
  <result pre="from H5N1 InfectionJ. Infect. Dis.20122051562157010.1093/infdis/jis23222448011 44.DucatezM.F.BahlJ.GriffinY.Stigger-RosserE.FranksJ.BarmanS.VijaykrishnaD.WebbA.GuanY.WebsterR.G.Feasibility of reconstructed ancestral H5N1" exact="influenza" post="viruses for cross-clade protective vaccine developmentProc. Natl. Acad. Sci."/>
  <result pre="epitope-based diagnostics and vaccinesBMC Bioinformatics2006715310.1186/1471-2105-7-15316545123 65.Molero-AbrahamM.LafuenteE.M.FlowerD.R.RecheP.A.Selection of conserved epitopes from" exact="hepatitis" post="C virus for pan-populational stimulation of T-cell responsesClin. Dev."/>
  <result pre="cross-reactive and virus-specific T-cell populations after immunization with serologically distinct" exact="influenza" post="A virusesJ. Exp. Med.197714555756810.1084/jem.145.3.557233901 70.KreijtzJ.H.BodewesR.van AmerongenG.KuikenT.FouchierR.A.OsterhausA.D.RimmelzwaanG.F.Primary influenza A virus"/>
  <result pre="with serologically distinct influenza A virusesJ. Exp. Med.197714555756810.1084/jem.145.3.557233901 70.KreijtzJ.H.BodewesR.van AmerongenG.KuikenT.FouchierR.A.OsterhausA.D.RimmelzwaanG.F.Primary" exact="influenza" post="A virus infection induces cross-protective immunity against a lethal"/>
  <result pre="a heterosubtypic virus strain in miceVaccine20072561262010.1016/j.vaccine.2006.08.03617005299 71.ZweerinkH.J.CourtneidgeS.A.SkehelJ.J.CrumptonM.J.AskonasB.A.Cytotoxic T cells kill" exact="influenza" post="virus infected cells but do not distinguish between serologically"/>
  <result pre="cross-reactive CD4+ T-cell HA-epitopes of seasonal and the 2009 pandemic" exact="influenza" post="virusesInfluenza Other Respi. Viruses2010424925810.1111/j.1750-2659.2010.00161.x20716156 73.DuvvuriV.R.DuvvuriB.JamnikV.GubbayJ.B.WuJ.WuG.E.T cell memory to evolutionarily"/>
  <result pre="74.De GrootA.S.ArditoM.McClaineE.M.MoiseL.MartinW.D.Immunoinformatic comparison of T-cell epitopes contained in novel swine-origin" exact="influenza" post="A (H1N1) virus with epitopes in 2008–2009 conventional influenza"/>
  <result pre="swine-origin influenza A (H1N1) virus with epitopes in 2008–2009 conventional" exact="influenza" post="vaccineVaccine2009275740574710.1016/j.vaccine.2009.07.04019660593 75.GeX.TanV.BollykyP.L.StandiferN.E.JamesE.A.KwokW.W.Assessment of Seasonal Influenza A Virus-Specific CD4 T-Cell"/>
  <result pre="Influenza A VirusJ. Virol.2010843312331910.1128/JVI.02226-0920071564 76.GreenbaumJ.A.KotturiM.F.KimY.OseroffC.VaughanK.SalimiN.VitaR.PonomarenkoJ.ScheuermannR.H.SetteA.et al.Pre-existing immunity against swine-origin H1N1" exact="influenza" post="viruses in the general human populationProc. Natl. Acad. Sci."/>
  <result pre="al.Preexisting influenza-specific CD4+ T cells correlate with disease protection against" exact="influenza" post="challenge in humansNat. Med.2012187428010.1038/nm.261222286307 79.ClinicalTrials.gov Identifier:NCT01265914 A Study to"/>
  <result pre="safety of different doses and formulations of a broad spectrum" exact="influenza" post="vaccine (FLU-v) developed by SEEK: Study protocol for a"/>
  <result pre="https://clinicaltrials.gov/ct2/show/NCT03450915?term=epitope&amp;amp;cond=Influenza&amp;amp;rank=6(accessed on 20 February 2019) 85.GottliebT.Ben-YedidiaT.Epitope-based approaches to a universal" exact="influenza" post="vaccineJ. Autoimmun.201454152010.1016/j.jaut.2014.07.00525172355 86.AtsmonJ.CaracoY.Ziv-SeferS.ShaikevichD.AbramovE.VolokhovI.BruzilS.HaimaK.Y.GottliebT.Ben-YedidiaT.Priming by a novel universal influenza vaccine"/>
  <result pre="a universal influenza vaccineJ. Autoimmun.201454152010.1016/j.jaut.2014.07.00525172355 86.AtsmonJ.CaracoY.Ziv-SeferS.ShaikevichD.AbramovE.VolokhovI.BruzilS.HaimaK.Y.GottliebT.Ben-YedidiaT.Priming by a novel universal" exact="influenza" post="vaccine (Multimeric-001)—A gateway for improving immune response in the"/>
  <result pre="108.BaeleG.SuchardM.A.RambautA.LemeyP.Emerging Concepts of Data Integration in Pathogen PhylodynamicsSyst. Biol.201766e47e6510.1093/sysbio/syw05428173504 109.KirkpatrickE.QiuX.WilsonP.C.BahlJ.KrammerF.The" exact="influenza" post="virus hemagglutinin head evolves faster than the stalk domainSci."/>
  <result pre="evolutionary models improve phylogenetic reconstruction for emerging, seasonal, and pandemic" exact="influenza" post="virusesbioRxiv201710.1101/228692 111.KleinmanC.L.RodrigueN.LartillotN.PhilippeH.Statistical Potentials for Improved Structurally Constrained Evolutionary ModelsMol."/>
  <result pre="VirusPLOS Pathog.201612e100585610.1371/journal.ppat.100585627571422 127.ThyagarajanB.BloomJ.D.The inherent mutational tolerance and antigenic evolvability of" exact="influenza" post="hemagglutininElife2014310.7554/eLife.03300 128.BloomJ.D.GongL.I.BaltimoreD.Permissive Secondary Mutations Enable the Evolution of Influenza"/>
  <result pre="Computational identification of selective sweeps to monitor the adaptation of" exact="influenza" post="A virusesSci. Rep.2018837310.1038/s41598-017-18791-z29321538 131.AmpofoW.K.Azziz-BaumgartnerE.BashirU.CoxN.J.FasceR.GiovanniM.GrohmannG.HuangS.KatzJ.MironenkoA.et al.Strengthening the influenza vaccine virus"/>
  <result pre="the adaptation of influenza A virusesSci. Rep.2018837310.1038/s41598-017-18791-z29321538 131.AmpofoW.K.Azziz-BaumgartnerE.BashirU.CoxN.J.FasceR.GiovanniM.GrohmannG.HuangS.KatzJ.MironenkoA.et al.Strengthening the" exact="influenza" post="vaccine virus selection and development processVaccine2015334368438210.1016/j.vaccine.2015.06.09026148877 132.collab: Institute of"/>
  <result pre="Academies Press (US)Washington, DC, USA2010 133.HoyeB.J.MunsterV.J.NishiuraH.KlaassenM.FouchierR.A.Surveillance of wild birds for" exact="avian influenza" post="virusEmerg. Infect. Dis.2010161827183410.3201/eid1612.10058921122209 134.SquiresR.B.NoronhaJ.HuntV.García-SastreA.MackenC.BaumgarthN.SuarezD.PickettB.E.ZhangY.LarsenC.N.Influenza research database: An integrated bioinformatics"/>
  <result pre="Press (US)Washington, DC, USA2010 133.HoyeB.J.MunsterV.J.NishiuraH.KlaassenM.FouchierR.A.Surveillance of wild birds for avian" exact="influenza" post="virusEmerg. Infect. Dis.2010161827183410.3201/eid1612.10058921122209 134.SquiresR.B.NoronhaJ.HuntV.García-SastreA.MackenC.BaumgarthN.SuarezD.PickettB.E.ZhangY.LarsenC.N.Influenza research database: An integrated bioinformatics"/>
  <result pre="Infect. Dis.2010161827183410.3201/eid1612.10058921122209 134.SquiresR.B.NoronhaJ.HuntV.García-SastreA.MackenC.BaumgarthN.SuarezD.PickettB.E.ZhangY.LarsenC.N.Influenza research database: An integrated bioinformatics resource for" exact="influenza" post="research and surveillanceInfluenza Other Respi. Viruses2012640441610.1111/j.1750-2659.2011.00331.x22260278 135.GunnarssonG.Latorre-MargalefN.HobsonK.A.Van WilgenburgS.L.ElmbergJ.OlsenB.FouchierR.A.M.WaldenströmJ.Disease dynamics"/>
  <result pre="bird migration––Linking mallards Anas platyrhynchos and subtype diversity of the" exact="influenza" post="A virus in time and spacePLoS ONE20127e3567910.1371/journal.pone.003567922536424 136.ElbeS.Buckland-MerrettG.Data, disease"/>
  <result pre="are modeled to understand the susceptibility and immune response to" exact="influenza" post="viruses by studying the host immunogenetics, for example, the"/>
  <result pre="ecological determinants that affect viral evolution and host immunity to" exact="influenza" post="virus. In order to generate critical components for vaccine"/>
  <result pre="high-quality information and broad-reactive components for a universal vaccine of" exact="influenza" post="viruses. Figure 2 Framework for computational influenza universal vaccine"/>
  <result pre="universal vaccine of influenza viruses. Figure 2 Framework for computational" exact="influenza" post="universal vaccine design. (A) Model-free consensus-based optimized approach. Consensus"/>
  <result pre="domains. Based on the evolutionary relationship among different subtypes of" exact="influenza" post="A virus, common ancestral sequences of head and stalk"/>
  <result pre="sequences of head and stalk domains can be generated within" exact="influenza" post="A virus Group 1 (H1, H2, H5, H6, H7,"/>
  <result pre="approaches should be used for all the gene segments of" exact="influenza" post="viruses to generate a full profile of viral immunogenicity."/>
  <result pre="viral immunogenicity. vaccines-07-00045-t001_Table 1Table 1 Summary and examples of computational" exact="influenza" post="universal vaccine design. Approach Conceptual Design Evidence-Level Advantages Disadvantages"/>
  <result pre="the same subtype;(3) Neutralize the receptor binding sites to prevent" exact="influenza" post="disease with a clear path towards clinical proof of"/>
  <result pre="2B Pre-clinical (1) Induce broad cross-reactive protection within highly diverse" exact="influenza" post="subtype(2) Account for sampling bias and the variability of"/>
  <result pre="Table 2 for details vaccines-07-00045-t002_Table 2Table 2 Promising epitope-based universal" exact="influenza" post="vaccines at clinical trials. Vaccine Company Projects Clinical Phase"/>
 </snippets>
</snippetsTree>
